Abington Neurological Associates is one of the few centers in the region offering experimental treatment options for Alzheimer’s disease.
A 2009 double-blind, placebo-controlled trial found significant improvements in cognitive functioning among patients who took Axona. The results were best for those who were negative for the APOE4 mutation, which increases risk for developing Alzheimer’s. On a 70-point cognitive test, patients without this mutation scored 4.77 to 6.26 points better than the placebo group at 45 days, and 3.36 to 5.33 points better at 90 days.
Click here to read the article from the Philadelphia Inquirer.
Visit our Clinical Research page to learn more about the current studies at Abington Neurological Associates.